A Phase 1 Open Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications

Sponsor:

AbbVie, Inc

Sponsor Study ID:

M24-427

CTO #:

103955

NCT Number:

NCT06084481

Phase:

I

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Anus; Bladder; Cervix Uteri; Colon; Esophagus; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid

Study Objectives:

To assess the efficacy of ABBV-400 in each solid tumor indication, including advanced or metastatic HCC, BTC, PDAC, ESCC, TNBC, HR+/HER2- BC and HNSCC. To characterize the safety and tolerability of ABBV-400 as monotherapy in advanced or metastatic HCC, BTC, PDAC, ESCC, TNBC, HR+/HER2- BC, and HNSCC.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)